MXPA04002996A - Peptidicos de tipo glucagon glp1 y tratamiento de insuficiencia respiratoria. - Google Patents

Peptidicos de tipo glucagon glp1 y tratamiento de insuficiencia respiratoria.

Info

Publication number
MXPA04002996A
MXPA04002996A MXPA04002996A MXPA04002996A MXPA04002996A MX PA04002996 A MXPA04002996 A MX PA04002996A MX PA04002996 A MXPA04002996 A MX PA04002996A MX PA04002996 A MXPA04002996 A MX PA04002996A MX PA04002996 A MXPA04002996 A MX PA04002996A
Authority
MX
Mexico
Prior art keywords
glp
glucagon
respiratory distress
peptides
treatment
Prior art date
Application number
MXPA04002996A
Other languages
English (en)
Inventor
Anthony Jakubowski Joseph
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA04002996A publication Critical patent/MXPA04002996A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion describe el uso de compuestos peptidicos del tipo glucagon (GLP-1) para reducir la mortalidad y morbilidad asociada a enfermedades criticas donde el paciente esta predispuesto a/o sufre algun tipo de insuficiencia respiratoria.
MXPA04002996A 2001-10-01 2002-09-19 Peptidicos de tipo glucagon glp1 y tratamiento de insuficiencia respiratoria. MXPA04002996A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32633001P 2001-10-01 2001-10-01
PCT/US2002/028123 WO2003028626A2 (en) 2001-10-01 2002-09-19 Glucagon-like peptides (glp-1) and treatment of respiratory distress

Publications (1)

Publication Number Publication Date
MXPA04002996A true MXPA04002996A (es) 2004-07-15

Family

ID=23271764

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002996A MXPA04002996A (es) 2001-10-01 2002-09-19 Peptidicos de tipo glucagon glp1 y tratamiento de insuficiencia respiratoria.

Country Status (19)

Country Link
US (2) US20040235726A1 (es)
EP (1) EP1443952A4 (es)
JP (1) JP2005523877A (es)
KR (1) KR20040040482A (es)
CN (1) CN1561224A (es)
BR (1) BR0212620A (es)
CA (1) CA2462543A1 (es)
CZ (1) CZ2004441A3 (es)
EA (1) EA200400501A1 (es)
EC (1) ECSP045044A (es)
HR (1) HRP20040258A2 (es)
HU (1) HUP0600437A2 (es)
IL (1) IL160631A0 (es)
MX (1) MXPA04002996A (es)
NO (1) NO20041351L (es)
PL (1) PL373846A1 (es)
SK (1) SK1432004A3 (es)
WO (1) WO2003028626A2 (es)
ZA (1) ZA200402557B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001254621A1 (en) 2000-05-05 2001-11-20 K.U. Leuven R And D Critical illness neuropathy
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
AU2003203146A1 (en) * 2002-02-07 2003-09-02 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2003072143A1 (en) * 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
CA2551039C (en) 2003-12-16 2013-01-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Analogues of glp-1
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
NZ565535A (en) 2005-06-30 2011-03-31 Ipsen Pharma Sas GLP-1 pharmaceutical compositions
EP3449946A3 (en) 2005-12-19 2020-11-04 PharmaIN Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
EP2574624A1 (en) 2006-04-20 2013-04-03 Amgen Inc. GLP-1 compounds
JP2010043001A (ja) * 2006-11-09 2010-02-25 Sanwa Kagaku Kenkyusho Co Ltd Glp−1誘導体とその用途
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2010029159A1 (en) 2008-09-12 2010-03-18 Novo Nordisk A/S Method of acylating a peptide or protein
DK2344519T3 (en) 2008-11-07 2017-01-23 Massachusetts Gen Hospital C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1)
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
DE102009024229B3 (de) * 2009-06-08 2010-10-14 Salzsieder, Eckhard, Dipl.-Phys., Dr. rer.nat. Indikationseinrichtung zur automatisierten Bestimmung des individuellen Inkretin-Sensitivitäts-Indexes eines Probanden
MX2013000250A (es) 2010-07-02 2013-10-28 Angiochem Inc Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos.
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
EP2820038B1 (en) * 2012-03-01 2020-06-17 Novo Nordisk A/S Glp-1 prodrugs
WO2021222535A1 (en) * 2020-05-01 2021-11-04 Irazu Bio Method for treating respiratory viral infections comprising administration of fatty acid compositions
CN116847868A (zh) * 2021-01-29 2023-10-03 韩美药品株式会社 用于预防或治疗肺部疾病的包括gip衍生物或其长效共轭物的药学组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6271241B1 (en) * 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors

Also Published As

Publication number Publication date
NO20041351L (no) 2004-06-30
PL373846A1 (en) 2005-09-19
EP1443952A4 (en) 2005-09-07
CZ2004441A3 (cs) 2004-11-10
ECSP045044A (es) 2004-04-28
IL160631A0 (en) 2004-07-25
HUP0600437A2 (en) 2006-09-28
CN1561224A (zh) 2005-01-05
KR20040040482A (ko) 2004-05-12
US20040235726A1 (en) 2004-11-25
US20080032932A1 (en) 2008-02-07
SK1432004A3 (sk) 2005-03-04
WO2003028626A3 (en) 2003-10-09
JP2005523877A (ja) 2005-08-11
EA200400501A1 (ru) 2005-06-30
CA2462543A1 (en) 2003-04-10
BR0212620A (pt) 2005-09-20
WO2003028626A2 (en) 2003-04-10
ZA200402557B (en) 2005-05-09
HRP20040258A2 (en) 2004-12-31
NO20041351D0 (no) 2004-03-31
EP1443952A2 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
MXPA04002996A (es) Peptidicos de tipo glucagon glp1 y tratamiento de insuficiencia respiratoria.
HRP20020996B1 (en) Glucagon-like peptide-1 analogs
TW200626613A (en) Analogues of GLP-1
MXPA04001560A (es) Premezclas de glp-1 e insulina basal.
AU3888893A (en) Use of a peptide
AU3441400A (en) Peptide
DE68929217D1 (en) Insulinotropes hormon
EP2298401A3 (en) Headgear for a breathing mask
DK1531791T3 (da) Forebyggelse og begrænsning af iskæmi
DE69129226D1 (de) Glp-1-analoga verwendbar in der diabetesbehandlung
MXPA04005906A (es) Cis-2,4,5-trifenil-.imidazolinas y uso de la misma para tratamiento de tumores.
EP1411968A4 (en) GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF
EE03775B1 (et) Kopsusurfaktandi valgu SP-C sünteetilised peptiidanaloogid
HUP0501192A3 (en) Glucagon-like peptide-1 analogs
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
DK1349578T3 (da) Kombinationspræparat indeholdende en biguanin (metformin) og arginin
HK1044957A1 (en) Medical use of mechanism-oriented inhibitiors of dipeptidyl peptidase i.
MXPA03006866A (es) Modificacion cristalina de depsipeptido ciclico con actividad mejorada.
PT1077068E (pt) Utilizacao do interferao alfa 5 no tratamento de hepatopatias virais
DE50104446D1 (de) Schlankheitsgurt
EP0919567A4 (en) NEW PEPTIDES AND NOOTROPER ACTIVE SUBSTANCES
KR20000015436U (ko) 원적외선을 방사하는 넥타이
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos
AU2002314005A1 (en) Recombinant expression of hhbv reverse transcriptase (rt)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal